<p><strong>Pediatric use</strong>: The safety and effectiveness of subcutaneous injections of Insulin Glulisine have been established in pediatric patients (age 4 to 17 years) with type 1 diabetes. Insulin Glulisine has not been studied in pediatric patients with type 1 diabetes younger than 4 years of age and in pediatric patients with type 2 diabetes. As in adults, the dosage of Insulin Glulisine must be individualized in pediatric patients based on metabolic needs and frequent monitoring of blood glucose<br />
<br />
<strong>Geriatric use</strong>: In clinical trials (n=2408), Insulin Glulisine was administered to 147 patients &ge;65 years of age and 27 patients &ge;75 years of age. The majority of this small subset of elderly patients had type 2 diabetes. The change in HbA1c values and hypoglycemia frequencies did not differ by age. Nevertheless, caution should be exercised when Insulin Glulisine is administered to geriatric patients.<br />
<br />
<strong>Renal impairment</strong>: Dose reduction may be needed<br />
<br />
<strong>Hepatic impairment</strong>: Dose reduction may be needed</p>